{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:41:10Z","timestamp":1707525670663},"reference-count":74,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,8]]},"DOI":"10.7759\/cureus.51899","type":"journal-article","created":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T03:28:20Z","timestamp":1704770900000},"source":"Crossref","is-referenced-by-count":0,"title":["Stevens-Johnson Syndrome From Combined Allopurinol and Angiotensin-Converting Enzyme Inhibitors: A Narrative Review"],"prefix":"10.7759","author":[{"given":"Isabella  M","family":"Fabian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirsten","family":"Maddox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cameron","family":"Robicheaux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahib  K","family":"Islam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Anwar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley","family":"Dorius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher L","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam M","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giustino","family":"Varrassi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahab","family":"Ahmadzadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sahar","family":"Shekoohi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan D","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.04.027","article-title":"Stevens-Johnson syndrome\/toxic epidermal necrolysis: a multicenter retrospective study of 377 adult patients from the United States","volume":"138","author":"Micheletti RG","year":"2018","unstructured":"Micheletti RG, Chiesa-Fuxench Z, Noe MH, et al.. Stevens-Johnson syndrome\/toxic epidermal necrolysis: a multicenter retrospective study of 377 adult patients from the United States. J Invest Dermatol. 2018, 138:2315-21. 10.1016\/j.jid.2018.04.027","journal-title":"J Invest Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.4103\/0019-5154.96192","article-title":"Causative drugs and clinical outcome in Stevens Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS-TEN overlap in children","volume":"57","author":"Sethuraman G","year":"2012","unstructured":"Sethuraman G, Sharma VK, Pahwa P, Khetan P. Causative drugs and clinical outcome in Stevens Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS-TEN overlap in children. Indian J Dermatol. 2012, 57:199-200. 10.4103\/0019-5154.96192","journal-title":"Indian J Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/medicina57090895","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of diagnosis and management","volume":"57","author":"Frantz R","year":"2021","unstructured":"Frantz R, Huang S, Are A, Motaparthi K. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of diagnosis and management. Medicina (Kaunas). 2021, 57:10.3390\/medicina57090895","journal-title":"Medicina (Kaunas)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-5-39","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome","volume":"5","author":"Harr T","year":"2010","unstructured":"Harr T, French LE. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Orphanet J Rare Dis. 2010, 5:39. 10.1186\/1750-1172-5-39","journal-title":"Orphanet J Rare Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-6175.2005.04556.x","article-title":"Angiotensin-converting enzyme inhibitors\u2019 side effects\u2014physiologic and non-physiologic considerations","volume":"7","author":"Sica DA","year":"2007","unstructured":"Sica DA. Angiotensin-converting enzyme inhibitors\u2019 side effects\u2014physiologic and non-physiologic considerations. J Clin Hypertens (Greenwich). 2007, 7:17-23. 10.1111\/j.1524-6175.2005.04556.x","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"ref6","unstructured":"5 Allopurinol Interactions to Watch Out for GoodRx. (2023). Accessed. August 6, 2023: https:\/\/www.goodrx.com\/allopurinol\/interactions."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(84)91807-5","article-title":"Fatal Stevens-Johnson syndrome in a patient on captopril and allopurinol","volume":"323","author":"Pennell DJ","year":"1984","unstructured":"Pennell DJ, Nunan TO, O\u2019Doherty MJ, Croft DN. Fatal Stevens-Johnson syndrome in a patient on captopril and allopurinol. Lancet. 1984, 323:463. 10.1016\/S0140-6736(84)91807-5","journal-title":"Lancet"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1378\/chest.108.2.586","article-title":"Allopurinol and enalapril. Drug induced anaphylactic coronary spasm and acute myocardial infarction","volume":"108","author":"Ahmad S","year":"1995","unstructured":"Ahmad S. Allopurinol and enalapril. Drug induced anaphylactic coronary spasm and acute myocardial infarction. Chest. 1995, 108:586. 10.1378\/chest.108.2.586","journal-title":"Chest"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2165\/11533190-000000000-00000","article-title":"Allopurinol in dermatology","volume":"11","author":"Tsai TF","year":"2010","unstructured":"Tsai TF, Yeh TY. Allopurinol in dermatology. Am J Clin Dermatol. 2010, 11:225-32. 10.2165\/11533190-000000000-00000","journal-title":"Am J Clin Dermatol"},{"key":"ref10","article-title":"Drug interactions and gout treatment","author":"Baxter K","year":"2010","unstructured":"Baxter K, Sharp J, Marshall A. Drug interactions and gout treatment. Phar J. 2010,","journal-title":"Phar J"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-017-0530-y","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: a concise review with a comprehensive summary of therapeutic interventions emphasizing supportive measures","volume":"34","author":"Schneider JA","year":"2017","unstructured":"Schneider JA, Cohen PR. Stevens-Johnson syndrome and toxic epidermal necrolysis: a concise review with a comprehensive summary of therapeutic interventions emphasizing supportive measures. Adv Ther. 2017, 34:1235-44. 10.1007\/s12325-017-0530-y","journal-title":"Adv Ther"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.12788\/j.sder.0058","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: clinical patterns, diagnostic considerations, etiology, and therapeutic management","volume":"33","author":"Mockenhaupt M","year":"2014","unstructured":"Mockenhaupt M. Stevens-Johnson syndrome and toxic epidermal necrolysis: clinical patterns, diagnostic considerations, etiology, and therapeutic management. Semin Cutan Med Surg. 2014, 33:10-6. 10.12788\/j.sder.0058","journal-title":"Semin Cutan Med Surg"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.4065\/mcp.2009.0379","article-title":"Clinical, etiologic, and histopathologic features of Stevens-Johnson syndrome during an 8-year period at Mayo Clinic","volume":"85","author":"Wetter DA","year":"2010","unstructured":"Wetter DA, Camilleri MJ. Clinical, etiologic, and histopathologic features of Stevens-Johnson syndrome during an 8-year period at Mayo Clinic. Mayo Clin Proc. 2010, 85:131-8. 10.4065\/mcp.2009.0379","journal-title":"Mayo Clin Proc"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0198582","article-title":"Life-threatening dermatoses: Stevens-Johnson syndrome and toxic epidermal necrolysis. Impact on the Spanish public health system (2010-2015)","volume":"13","author":"Velasco-Tirado V","year":"2018","unstructured":"Velasco-Tirado V, Alonso-Sard\u00f3n M, Cosano-Quero A, et al.. Life-threatening dermatoses: Stevens-Johnson syndrome and toxic epidermal necrolysis. Impact on the Spanish public health system (2010-2015). PLoS One. 2018, 13:e0198582. 10.1371\/journal.pone.0198582","journal-title":"PLoS One"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1080\/07853890701753664","article-title":"Stevens-Johnson syndrome: pathogenesis, diagnosis, and management","volume":"40","author":"Hazin R","year":"2008","unstructured":"Hazin R, Ibrahimi OA, Hazin MI, Kimyai-Asadi A. Stevens-Johnson syndrome: pathogenesis, diagnosis, and management. Ann Med. 2008, 40:129-38. 10.1080\/07853890701753664","journal-title":"Ann Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1590\/1806-9282.62.05.468","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: a review","volume":"62","author":"Wong A","year":"2016","unstructured":"Wong A, Malvestiti AA, Hafner Mde F. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review. Rev Assoc Med Bras (1992). 2016, 62:468-73. 10.1590\/1806-9282.62.05.468","journal-title":"Rev Assoc Med Bras (1992)"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/ped.13613","article-title":"Clinical features of Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"60","author":"Sato S","year":"2018","unstructured":"Sato S, Kanbe T, Tamaki Z, et al.. Clinical features of Stevens-Johnson syndrome and toxic epidermal necrolysis. Pediatr Int. 2018, 60:697-702. 10.1111\/ped.13613","journal-title":"Pediatr Int"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-0960.1999.00342.x","article-title":"Clinical manifestations and outcomes in 17 cases of Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"40","author":"Wong KC","year":"1999","unstructured":"Wong KC, Kennedy PJ, Lee S. Clinical manifestations and outcomes in 17 cases of Stevens-Johnson syndrome and toxic epidermal necrolysis. Australas J Dermatol. 1999, 40:131-4. 10.1046\/j.1440-0960.1999.00342.x","journal-title":"Australas J Dermatol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1159\/000354918","article-title":"Clinical features and prognostic factors in severe cutaneous drug reactions","volume":"162","author":"Yang MS","year":"2013","unstructured":"Yang MS, Kang MG, Jung JW, Song WJ, Kang HR, Cho SH, Min KU. Clinical features and prognostic factors in severe cutaneous drug reactions. Int Arch Allergy Immunol. 2013, 162:346-54. 10.1159\/000354918","journal-title":"Int Arch Allergy Immunol"},{"key":"ref20","article-title":"Causes and treatment outcomes of Stevens-Johnson syndrome and toxic epidermal necrolysis in 82 adult patients","volume":"27","author":"Kim HI","year":"2012","unstructured":"Kim HI, Kim SW, Park GY, et al.. Causes and treatment outcomes of Stevens-Johnson syndrome and toxic epidermal necrolysis in 82 adult patients. Korean J Intern Med. 2012, 27:203-10.","journal-title":"Korean J Intern Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-genom-083115-022324","article-title":"Drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis call for optimum patient stratification and theranostics via pharmacogenomics","volume":"19","author":"Sukasem C","year":"2018","unstructured":"Sukasem C, Katsila T, Tempark T, Patrinos GP, Chantratita W. Drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis call for optimum patient stratification and theranostics via pharmacogenomics. Annu Rev Genomics Hum Genet. 2018, 19:329-53. 10.1146\/annurev-genom-083115-022324","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00661-0","article-title":"Culprit medications and risk factors associated with Stevens-Johnson syndrome and toxic epidermal necrolysis: population-based nested case-control study","volume":"23","author":"Gronich N","year":"2022","unstructured":"Gronich N, Maman D, Stein N, Saliba W. Culprit medications and risk factors associated with Stevens-Johnson syndrome and toxic epidermal necrolysis: population-based nested case-control study. Am J Clin Dermatol. 2022, 23:257-66. 10.1007\/s40257-021-00661-0","journal-title":"Am J Clin Dermatol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.08.036","article-title":"Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel","volume":"58","author":"Halevy S","year":"2008","unstructured":"Halevy S, Ghislain PD, Mockenhaupt M, et al.. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol. 2008, 58:25-32. 10.1016\/j.jaad.2007.08.036","journal-title":"J Am Acad Dermatol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdin.2022.12.002","article-title":"Risk factors and drugs that trigger the onset of Stevens-Johnson syndrome and toxic epidermal necrolysis: a population-based cohort study using the Shizuoka Kokuho database","volume":"11","author":"Ubukata N","year":"2023","unstructured":"Ubukata N, Nakatani E, Hashizume H, Sasaki H, Miyachi Y. Risk factors and drugs that trigger the onset of Stevens-Johnson syndrome and toxic epidermal necrolysis: a population-based cohort study using the Shizuoka Kokuho database. JAAD Int. 2023, 11:24-32. 10.1016\/j.jdin.2022.12.002","journal-title":"JAAD Int"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.21037\/apm-21-341","article-title":"Toxic epidermal necrolysis with systemic lupus erythematosus: case report and review of the literature","volume":"11","author":"Fan WY","year":"2022","unstructured":"Fan WY, Zhai QR, Ma QB, Ge HX. Toxic epidermal necrolysis with systemic lupus erythematosus: case report and review of the literature. Ann Palliat Med. 2022, 11:2144-51. 10.21037\/apm-21-341","journal-title":"Ann Palliat Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16891","article-title":"Chronic pain: a long-term sequela of epidermal necrolysis (Stevens-Johnson syndrome\/toxic epidermal necrolysis) - prevalence, clinical characteristics and risk factors","volume":"35","author":"Lefaucheur JP","year":"2021","unstructured":"Lefaucheur JP, Valeyrie-Allanore L, Ng Wing Tin S, et al.. Chronic pain: a long-term sequela of epidermal necrolysis (Stevens-Johnson syndrome\/toxic epidermal necrolysis) - prevalence, clinical characteristics and risk factors. J Eur Acad Dermatol Venereol. 2021, 35:188-94. 10.1111\/jdv.16891","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-74588-6_195","article-title":"Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN): immunologic reactions","author":"Zimmerman D","year":"2019","unstructured":"Zimmerman D, Dang NH. Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN): immunologic reactions. Oncologic Critical Care. 2019, 267-80. 10.1007\/978-3-319-74588-6_195","journal-title":"Oncologic Critical Care"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)60789-2","article-title":"Pathogenesis and recent therapeutic trends in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"97","author":"Khalili B","year":"2006","unstructured":"Khalili B, Bahna SL. Pathogenesis and recent therapeutic trends in Stevens-Johnson syndrome and toxic epidermal necrolysis.  Ann Allergy Asthma Immunol. 2006, 97:272-81. 10.1016\/S1081-1206(10)60789-2","journal-title":"Ann Allergy Asthma Immunol"},{"key":"ref29","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand","volume":"162","author":"Abe R","year":"2003","unstructured":"Abe R, Shimizu T, Shibaki A, Nakamura H, Watanabe H, Shimizu H. Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand. Am J Pathol. 2003, 162:1515-20.","journal-title":"Am J Pathol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsi.2013.09.002","article-title":"Update on pathobiology in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"31","author":"Su SC","year":"2013","unstructured":"Su SC, Chung WH. Update on pathobiology in Stevens-Johnson syndrome and toxic epidermal necrolysis. Dermatol Sinica. 2013, 31:175-80. 10.1016\/j.dsi.2013.09.002","journal-title":"Dermatol Sinica"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.588063","article-title":"Current pharmacogenetic perspective on Stevens-Johnson syndrome and toxic epidermal necrolysis","author":"Cheng L","year":"2021","unstructured":"Cheng L. Current pharmacogenetic perspective on Stevens-Johnson syndrome and toxic epidermal necrolysis. Front Pharmacol. 2021, 12:588063. Accessed: August 12, 2023: https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.588063. 10.3389\/fphar.2021.588063"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-199508000-00011","article-title":"A slow acetylator genotype is a risk factor for sulphonamide-induced toxic epidermal necrolysis and Stevens-Johnson syndrome","volume":"5","author":"Wolkenstein P","year":"1995","unstructured":"Wolkenstein P, Carri\u00e8re V, Charue D, et al.. A slow acetylator genotype is a risk factor for sulphonamide-induced toxic epidermal necrolysis and Stevens-Johnson syndrome. Pharmacogenetics. 1995, 5:255-8. 10.1097\/00008571-199508000-00011","journal-title":"Pharmacogenetics"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.2332\/allergolint.55.9","article-title":"Toxic epidermal necrolysis and Stevens Johnson syndrome: our current understanding","volume":"55","author":"French LE","year":"2006","unstructured":"French LE. Toxic epidermal necrolysis and Stevens Johnson syndrome: our current understanding. Allergol Int. 2006, 55:9-16. 10.2332\/allergolint.55.9","journal-title":"Allergol Int"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-7843.2012.00868.x","article-title":"Association between HLA and Stevens-Johnson syndrome induced by carbamazepine in Southern Han Chinese: genetic markers besides B*1502?","volume":"111","author":"Shi YW","year":"2012","unstructured":"Shi YW, Min FL, Qin B, et al.. Association between HLA and Stevens-Johnson syndrome induced by carbamazepine in Southern Han Chinese: genetic markers besides B*1502?. Basic Clin Pharmacol Toxicol. 2012, 111:58-64. 10.1111\/j.1742-7843.2012.00868.x","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2013.4114","article-title":"Relationship between the HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"149","author":"Tangamornsuksan W","year":"2013","unstructured":"Tangamornsuksan W, Chaiyakunapruk N, Somkrua R, Lohitnavy M, Tassaneeyakul W. Relationship between the HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. JAMA Dermatol. 2013, 149:1025-32. 10.1001\/jamadermatol.2013.4114","journal-title":"JAMA Dermatol"},{"key":"ref36","unstructured":"Association of Hla-B*5801 Allele and Allopurinol-Induced Stevens Johnson Syndrome and Toxic Epidermal Necrolysis. A Systematic Review and Meta-Analysis | SpringerLink. Accessed: August 12, 2023: https:\/\/link.springer.com\/article\/10.1186\/1471-2350-12-118."},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0b013e3282f3ef9c","article-title":"A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs","volume":"18","author":"Lonjou C","year":"2008","unstructured":"Lonjou C, Borot N, Sekula P, et al.. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics. 2008, 18:99-107. 10.1097\/FPC.0b013e3282f3ef9c","journal-title":"Pharmacogenet Genomics"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.4103\/ijd.IJD_583_17","article-title":"Management of Stevens-Johnson syndrome-toxic epidermal necrolysis: looking beyond guidelines!","volume":"63","author":"Kumar R","year":"2018","unstructured":"Kumar R, Das A, Das S. Management of Stevens-Johnson syndrome-toxic epidermal necrolysis: looking beyond guidelines!. Indian J Dermatol. 2018, 63:117-24. 10.4103\/ijd.IJD_583_17","journal-title":"Indian J Dermatol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-023-02631-7","article-title":"Post-acute phase and sequelae management of epidermal necrolysis: an international, multidisciplinary DELPHI-based consensus","volume":"18","author":"Ingen-Housz-Oro S","year":"2023","unstructured":"Ingen-Housz-Oro S, Schmidt V, Ameri MM, et al.. Post-acute phase and sequelae management of epidermal necrolysis: an international, multidisciplinary DELPHI-based consensus. Orphanet J Rare Dis. 2023, 18:33. 10.1186\/s13023-023-02631-7","journal-title":"Orphanet J Rare Dis"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15360","article-title":"Long-term complications of Stevens-Johnson syndrome\/toxic epidermal necrolysis (SJS\/TEN): the spectrum of chronic problems in patients who survive an episode of SJS\/TEN necessitates multidisciplinary follow-up","volume":"177","author":"Lee HY","year":"2017","unstructured":"Lee HY, Walsh SA, Creamer D. Long-term complications of Stevens-Johnson syndrome\/toxic epidermal necrolysis (SJS\/TEN): the spectrum of chronic problems in patients who survive an episode of SJS\/TEN necessitates multidisciplinary follow-up. Br J Dermatol. 2017, 177:924-35. 10.1111\/bjd.15360","journal-title":"Br J Dermatol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.1136","article-title":"Long-term physical and psychological outcomes of Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"157","author":"Hoffman M","year":"2021","unstructured":"Hoffman M, Chansky PB, Bashyam AR, et al.. Long-term physical and psychological outcomes of Stevens-Johnson syndrome\/toxic epidermal necrolysis. JAMA Dermatol. 2021, 157:712-5. 10.1001\/jamadermatol.2021.1136","journal-title":"JAMA Dermatol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.21364","article-title":"Recurrent Steven-Johnson\/toxic epidermal necrolysis overlap syndrome","volume":"14","author":"Toledo-Martinez JF","year":"2022","unstructured":"Toledo-Martinez JF, Galdamez-Carcamo EV, Somoza-Cano FJ, Padilla-Mantilla DA, Alvarenga-Alvarado KL. Recurrent Steven-Johnson\/toxic epidermal necrolysis overlap syndrome. Cureus. 2022, 14:e21364. 10.7759\/cureus.21364","journal-title":"Cureus"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.03.023","article-title":"Morbidity and mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis in United States adults","volume":"136","author":"Hsu DY","year":"2016","unstructured":"Hsu DY, Brieva J, Silverberg NB, Silverberg JI. Morbidity and mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis in United States adults. J Invest Dermatol\r\n. 2016, 136:1387-97. 10.1016\/j.jid.2016.03.023","journal-title":"J Invest Dermatol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2020.11.004","article-title":"Mortality and risk factors on admission in toxic epidermal necrolysis: a cohort study of 59 patients","volume":"70","author":"Watanabe T","year":"2021","unstructured":"Watanabe T, Go H, Saigusa Y, et al.. Mortality and risk factors on admission in toxic epidermal necrolysis: a cohort study of 59 patients. Allergol Int. 2021, 70:229-34. 10.1016\/j.alit.2020.11.004","journal-title":"Allergol Int"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.510","article-title":"Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"133","author":"Sekula P","year":"2013","unstructured":"Sekula P, Dunant A, Mockenhaupt M, et al.. Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. J Invest Dermatol. 2013, 133:1197-204. 10.1038\/jid.2012.510","journal-title":"J Invest Dermatol"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2015.09.001","article-title":"Retrospective analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in 87 Japanese patients--treatment and outcome","volume":"65","author":"Yamane Y","year":"2016","unstructured":"Yamane Y, Matsukura S, Watanabe Y, et al.. Retrospective analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in 87 Japanese patients--treatment and outcome. Allergol Int. 2016, 65:74-81. 10.1016\/j.alit.2015.09.001","journal-title":"Allergol Int"},{"key":"ref47","article-title":"Allopurinol","author":"Qurie A","year":"2023","unstructured":"Qurie A, Preuss CV, Musa R. Allopurinol. StatPearls. StatPearls, 2023."},{"key":"ref48","unstructured":"Allopurinol. (2023). Accessed.  August 6, 2023: https:\/\/go.drugbank.com\/drugs\/DB00437."},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1999.00041.x","article-title":"Pharmacokinetics and pharmacodynamics of allopurinol in elderly and young subjects","volume":"48","author":"Turnheim K","year":"1999","unstructured":"Turnheim K, Krivanek P, Oberbauer R. Pharmacokinetics and pharmacodynamics of allopurinol in elderly and young subjects. Br J Clin Pharmacol. 1999, 48:501-9. 10.1046\/j.1365-2125.1999.00041.x","journal-title":"Br J Clin Pharmacol"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006077.pub3","article-title":"Allopurinol for chronic gout","volume":"2014","author":"Seth R","year":"2014","unstructured":"Seth R, Kydd AS, Buchbinder R, Bombardier C, Edwards CJ. Allopurinol for chronic gout. Cochrane Database Syst Rev. 2014, 2014:CD006077. 10.1002\/14651858.CD006077.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2014.05.006","article-title":"Medical management of kidney stones: AUA guideline","volume":"192","author":"Pearle MS","year":"2014","unstructured":"Pearle MS, Goldfarb DS, Assimos DG, et al.. Medical management of kidney stones: AUA guideline. J Urol. 2014, 192:316-24. 10.1016\/j.juro.2014.05.006","journal-title":"J Urol"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2017.05.004","article-title":"Serum uric acid and risk of kidney stones","volume":"70","author":"Ferraro PM","year":"2017","unstructured":"Ferraro PM, Curhan GC. Serum uric acid and risk of kidney stones. Am J Kidney Dis. 2017, 70:158-9. 10.1053\/j.ajkd.2017.05.004","journal-title":"Am J Kidney Dis"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1080\/15257770600893974","article-title":"Efficacy and safety of allopurinol in patients with the Lesch-Nyhan syndrome and partial hypoxanthine-phosphoribosyltransferase deficiency: a follow-up study of 18 Spanish patients","volume":"25","author":"Torres RJ","year":"2006","unstructured":"Torres RJ, Prior C, Puig JG. Efficacy and safety of allopurinol in patients with the Lesch-Nyhan syndrome and partial hypoxanthine-phosphoribosyltransferase deficiency: a follow-up study of 18 Spanish patients. Nucleosides Nucleotides Nucleic Acids. 2006, 25:1077-82. 10.1080\/15257770600893974","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24180","article-title":"2020 American College of Rheumatology Guideline for the management of gout","volume":"72","author":"FitzGerald JD","year":"2020","unstructured":"FitzGerald JD, Dalbeth N, Mikuls T, et al.. 2020 American College of Rheumatology Guideline for the management of gout. Arthritis Care Res (Hoboken). 2020, 72:744-60. 10.1002\/acr.24180","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1971.03180310037007","article-title":"Severe hypersensitivity reactions associated with allopurinol","volume":"216","author":"Mills RM Jr","year":"1971","unstructured":"Mills RM Jr. Severe hypersensitivity reactions associated with allopurinol. JAMA. 1971, 216:799-802. 10.1001\/jama.1971.03180310037007","journal-title":"JAMA"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1007\/s40801-019-00174-7","article-title":"Severe cutaneous adverse drug reactions associated with allopurinol: an analysis of spontaneous reporting system in southern Italy","volume":"7","author":"Scavone C","year":"2020","unstructured":"Scavone C, Di Mauro C, Ruggiero R, et al.. Severe cutaneous adverse drug reactions associated with allopurinol: an analysis of spontaneous reporting system in southern Italy. Drugs Real World Outcomes. 2020, 7:41-51. 10.1007\/s40801-019-00174-7","journal-title":"Drugs Real World Outcomes"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/1503709","article-title":"Treatments for severe cutaneous adverse reactions","volume":"2017","author":"Cho YT","year":"2017","unstructured":"Cho YT, Chu CY. Treatments for severe cutaneous adverse reactions. J Immunol Res. 2017, 2017:1503709. 10.1155\/2017\/1503709","journal-title":"J Immunol Res"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5701033","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study","volume":"128","author":"Mockenhaupt M","year":"2008","unstructured":"Mockenhaupt M, Viboud C, Dunant A, et al.. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol. 2008, 128:35-44. 10.1038\/sj.jid.5701033","journal-title":"J Invest Dermatol"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2015.3536","article-title":"Allopurinol use and risk of fatal hypersensitivity reactions: a nationwide population-based study in Taiwan","volume":"175","author":"Yang CY","year":"2015","unstructured":"Yang CY, Chen CH, Deng ST, et al.. Allopurinol use and risk of fatal hypersensitivity reactions: a nationwide population-based study in Taiwan. JAMA Intern Med. 2015, 175:1550-7. 10.1001\/jamainternmed.2015.3536","journal-title":"JAMA Intern Med"},{"key":"ref60","article-title":"Angiotensin-Converting Enzyme Inhibitors (ACEI)","author":"Herman LL","year":"2023","unstructured":"Herman LL, Padala SA, Ahmed I, Bashir K. Angiotensin-Converting Enzyme Inhibitors (ACEI). StatPearls. StatPearls, 2023."},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003823.pub2","article-title":"Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension","volume":"2008","author":"Heran BS","year":"2008","unstructured":"Heran BS, Wong MM, Heran IK, Wright JM. Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension. Cochrane Database Syst Rev. 2008, 2008:CD003823. 10.1002\/14651858.CD003823.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.97.14.1411","article-title":"Angiotensin-converting enzyme inhibitors","volume":"97","author":"Brown NJ","year":"1998","unstructured":"Brown NJ, Vaughan DE. Angiotensin-converting enzyme inhibitors. Circulation. 1998, 97:1411-20. 10.1161\/01.cir.97.14.1411","journal-title":"Circulation"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199000392-00004","article-title":"Mechanism of action of angiotensin-converting enzyme (ACE) inhibitors in hypertension and heart failure. Role of plasma versus tissue ACE","volume":"39","author":"Dzau VJ","year":"1990","unstructured":"Dzau VJ. Mechanism of action of angiotensin-converting enzyme (ACE) inhibitors in hypertension and heart failure. Role of plasma versus tissue ACE. Drugs. 1990, 39:11-6. 10.2165\/00003495-199000392-00004","journal-title":"Drugs"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.01.058","article-title":"Angiotensin-converting enzyme inhibitors in hypertension: to use or not to use?","volume":"71","author":"Messerli FH","year":"2018","unstructured":"Messerli FH, Bangalore S, Bavishi C, Rimoldi SF. Angiotensin-converting enzyme inhibitors in hypertension: to use or not to use?. J Am Coll Cardiol. 2018, 71:1474-82. 10.1016\/j.jacc.2018.01.058","journal-title":"J Am Coll Cardiol"},{"key":"ref65","article-title":"Captopril","author":"Marte F","year":"2023","unstructured":"Marte F, Sankar P, Cassagnol M. Captopril. StatPearls. StatPearls, 2023."},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1007\/BF03259832","article-title":"Adverse reactions with angiotensin converting enzyme (ACE) inhibitors","volume":"1","author":"DiBianco R","year":"1986","unstructured":"DiBianco R. Adverse reactions with angiotensin converting enzyme (ACE) inhibitors. Med Toxicol. 1986, 1:122-41. 10.1007\/BF03259832","journal-title":"Med Toxicol"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(86)90945-9","article-title":"Safety profiles of the angiotensin converting enzyme inhibitors captopril and enalapril","volume":"81","author":"Irvin JD","year":"1986","unstructured":"Irvin JD, Viau JM. Safety profiles of the angiotensin converting enzyme inhibitors captopril and enalapril. Am J Med. 1986, 81:46-50. 10.1016\/0002-9343(86)90945-9","journal-title":"Am J Med"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(84)92190-1","article-title":"Fever, myalgia, and arthralgia in a patient on captopril and allopurinol","volume":"323","author":"Samanta A","year":"1984","unstructured":"Samanta A, Burden AC. Fever, myalgia, and arthralgia in a patient on captopril and allopurinol. Lancet. 1984, 323:679. 10.1016\/S0140-6736(84)92190-1","journal-title":"Lancet"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.22159\/ijap.2018.v10s1.29","article-title":"Drug interactions among patients with hypertension taking angiotensin converting enzyme inhibitors in an Indonesian hospital","volume":"10","author":"Sari S","year":"2018","unstructured":"Sari S, Darajat A, Nursanti B. Drug interactions among patients with hypertension taking angiotensin converting enzyme inhibitors in an Indonesian hospital. Int J Appl Pharm. 2018, 10:138. 10.22159\/ijap.2018.v10s1.29","journal-title":"Int J Appl Pharm"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-010-9442-5","article-title":"The incidence of potential drug-drug interactions in elderly patients with arterial hypertension","volume":"32","author":"Bacic-Vrca V","year":"2010","unstructured":"Bacic-Vrca V, Marusic S, Erdeljic V, Falamic S, Gojo-Tomic N, Rahelic D. The incidence of potential drug-drug interactions in elderly patients with arterial hypertension. Pharm World Sci. 2010, 32:815-21. 10.1007\/s11096-010-9442-5","journal-title":"Pharm World Sci"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-198814040-00002","article-title":"Pharmacokinetics of captopril in healthy subjects and in patients with cardiovascular diseases","volume":"14","author":"Duchin KL","year":"1988","unstructured":"Duchin KL, McKinstry DN, Cohen AI, Migdalof BH. Pharmacokinetics of captopril in healthy subjects and in patients with cardiovascular diseases. Clin Pharmacokinet. 1988, 14:241-59. 10.2165\/00003088-198814040-00002","journal-title":"Clin Pharmacokinet"},{"key":"ref72","article-title":"Side effects off allopurinol","volume":"124","author":"R\u00f8devand E","year":"2004","unstructured":"R\u00f8devand E, Sletvold O, Kvande KT. Side effects off allopurinol. Tidsskr Nor Laegeforen. 2004, 124:2618-9.","journal-title":"Tidsskr Nor Laegeforen"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1186\/s40780-016-0048-5","article-title":"Analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis using the Japanese Adverse Drug Event Report database","volume":"2","author":"Abe J","year":"2016","unstructured":"Abe J, Umetsu R, Mataki K, et al.. Analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis using the Japanese Adverse Drug Event Report database. J Pharm Health Care Sci. 2016, 2:14. 10.1186\/s40780-016-0048-5","journal-title":"J Pharm Health Care Sci"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1159\/000235731","article-title":"Combination of captopril and allopurinol retards fructose-induced metabolic syndrome","volume":"30","author":"Roncal CA","year":"2009","unstructured":"Roncal CA, Reungjui S, S\u00e1nchez-Lozada LG, Mu W, Sautin YY, Nakagawa T, Johnson RJ. Combination of captopril and allopurinol retards fructose-induced metabolic syndrome. Am J Nephrol. 2009, 30:399-404. 10.1159\/000235731","journal-title":"Am J Nephrol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/214999-stevens-johnson-syndrome-from-combined-allopurinol-and-angiotensin-converting-enzyme-inhibitors-a-narrative-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:14:41Z","timestamp":1707509681000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/214999-stevens-johnson-syndrome-from-combined-allopurinol-and-angiotensin-converting-enzyme-inhibitors-a-narrative-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,8]]},"references-count":74,"URL":"https:\/\/doi.org\/10.7759\/cureus.51899","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1,8]]}}}